Global Sorafenib Market Size, by Product Type (Chewable Tablets, Dissolving Strips, Liquid Sorafenib), Application (Bowl Diseases, Constipation, Diabetic Gastro Paresis) & Region - Key Manufacturers, Analysis, Growth Trends, and Forecast till 2026

  • Category : Healthcare and Pharma
  • |
  • ID : 1012298
  • |
  • Publishe Date : May 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Sorafenib Market was estimated to be valued at USD XX million in 2019 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. The market is primarily driven by increase in prevalence of chronic diseases like cancer. In addition, sorafenib are used in the treatment of liver cancer is likely to supplement the market growth in forecast period. However, drug shows adverse side effects when taken along with other drugs or radiotherapy might hamper the market growth.

The global Sorafenib market is primarily segmented based on different product type, application and regions.

On the basis of product type, the market is split into:
* Patented Drugs
* Generic Drugs
* Capsule
* Tablets

On the basis of Application, the market is split into:
* Kidney Cancer
* Liver Cancer
* Thyroid Cancer

Moreover, the market is classified based on regions and countries as follows:
* North America- U.S., Canada
* Europe- U.K., France, Germany, Italy and Rest of Europe
* Asia-Pacific- China, Japan, India and Rest of Asia Pacific
* South America- Brazil, Mexico and Rest of South America
* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players:
The key players profiled in the market include:
* Pfizer
* Allergan
* Alnylam Pharmaceuticals
* Acceleron Pharma
* Biocon
* Bionomics
* CASI Pharmaceuticals
* Celgene Corporation
* Enzon Pharmaceuticals
* Five Prime Therapeutics

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:
* Global, regional, country, product type and application market size and their forecast from 2015-2026
* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market
* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies
* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key products, and unique selling points
* Analysis on key players’ strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market
* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors’ short term and long term strategies
* Detailed insights on emerging regions, product type and application with qualitative and quantitative information and facts

Target Audience:
* Sorafenib Manufacturers
* Traders, Importers, and Exporters
* Raw Material Suppliers and Distributors
* Research and Consulting Firms
* Government and Research Organizations
* Associations and Industry Bodies

Research Methodology:
The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data sources, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:
* Manufacturers
* Suppliers
* Distributors
* Government Body & Associations
* Research Institutes

TABLE OF CONTENTS

1. Introduction

2. Research Methodology

3. Executive Summary

4. Global Sorafenib Market Overview
4.1. Market Segmentation & Scope
4.2. Market Trends
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Supply Chain Analysis
4.3. Global Sorafenib Market - Porter\'s Five Forces Analysis
4.4. Global Sorafenib Market - PESTEL Analysis

5. Global Sorafenib Market, by Product Type
5.1. Global Sorafenib Market, Size and Forecast, 2015-2026
5.2. Global Sorafenib Market, by Patented Drugs2015-2026
5.2.1. Key driving factors, trends and opportunities
5.2.2. Market size and forecast, 2015-2026
5.3. Global Sorafenib Market, by Generic Drugs, 2015-2026
5.3.1. Key driving factors, trends and opportunities
5.3.2. Market size and forecast, 2015-2026
5.4. Global Sorafenib Market, by Capsule, 2015-2026
5.4.1. Key driving factors, trends and opportunities
5.4.2. Market size and forecast, 2015-2026
5.5. Global Sorafenib Market, by Tablets, 2015-2026
5.5.1. Key driving factors, trends and opportunities
5.5.2. Market size and forecast, 2015-2026

6. Global Sorafenib Market, by Application
6.1. Global Sorafenib Market, Size and Forecast, 2015-2026
6.2. Global Sorafenib Market, by Kidney Cancer, 2015-2026
6.2.1. Key driving factors, trends and opportunities
6.2.2. Market size and forecast, 2015-2026
6.3. Global Sorafenib Market, by Liver Cancer, 2015-2026
6.3.1. Key driving factors, trends and opportunities
6.3.2. Market size and forecast, 2015-2026
6.4. Global Sorafenib Market, by Thyroid Cancer, 2015-2026
6.4.1. Key driving factors, trends and opportunities
6.4.2. Market size and forecast, 2015-2026

7. Global Sorafenib Market by Region
7.1. Sorafenib Market Regional Analysis, 2015-2026
7.2. Global Sorafenib Market Revenue (USD Million) by Region, 2015-2026
7.3. North America Sorafenib Market, 2015-2026
7.3.1. North America Sorafenib Market Size and Forecast, 2015-2026
7.3.2. North America Sorafenib Market by Country, 2015-2026
7.3.2.1. U.S. Sorafenib Market, 2015-2026
7.3.2.2. Canada Sorafenib Market, 2015-2026
7.4. Europe Sorafenib Market, 2015-2026
7.4.1. Europe Sorafenib Market Size and Forecast, 2015-2026
7.4.2. Europe Sorafenib Market by Country, 2015-2026
7.4.2.1. Germany Sorafenib Market, 2015-2026
7.4.2.2. France Sorafenib Market, 2015-2026
7.4.2.3. Italy Sorafenib Market, 2015-2026
7.4.2.4. UK Sorafenib Market, 2015-2026
7.4.2.5. Spain Sorafenib Market, 2015-2026
7.4.2.6. Rest of Europe Sorafenib Market, 2015-2026
7.5. Asia Pacific Sorafenib Market, 2015-2026
7.5.1. Asia Pacific Sorafenib Market Size and Forecast, 2015-2026
7.5.2. Asia Pacific Sorafenib Market by Country, 2015-2026
7.5.2.1. Japan Sorafenib Market, 2015-2026
7.5.2.2. China Sorafenib Market, 2015-2026
7.5.2.3. India Sorafenib Market, 2015-2026
7.5.2.4. Rest of Asia Pacific Sorafenib Market, 2015-2026
7.6. South America Sorafenib Market, 2015-2026
7.6.1. South America Sorafenib Market Size and Forecast, 2015-2026
7.6.2. South America Sorafenib Market by Country, 2015-2026
7.6.2.1. Mexico Sorafenib Market, 2015-2026
7.6.2.2. Brazil Sorafenib Market, 2015-2026
7.6.2.3. Rest of South America Sorafenib Market, 2015-2026
7.7. Middle East & Africa Sorafenib Market, 2015-2026
7.7.1. Middle East & Africa Sorafenib Market Size and Forecast, 2015-2026
7.7.2. Middle East & Africa Sorafenib Market by Country, 2015-2026
7.7.2.1. Saudi Arabia Sorafenib Market, 2015-2026
7.7.2.2. South Africa Sorafenib Market, 2015-2026
7.7.2.3. Rest of Middle East & Africa Sorafenib Market, 2015-2026

8. Competitive Landscape
8.1. Introduction
8.2. Market Share Analysis/Top Player Positioning, 2019

9. Company Profiles
9.1. Pfizer
9.1.1. Company Overview
9.1.2. Financial Overview
9.1.3. Product Benchmarking
9.1.4. Key Developments
9.2. Allergan
9.2.1. Company Overview
9.2.2. Financial Overview
9.2.3. Product Benchmarking
9.2.4. Key Developments
9.3. Alnylam Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Overview
9.3.3. Product Benchmarking
9.3.4. Key Developments
9.4. Acceleron Pharma
9.4.1. Company Overview
9.4.2. Financial Overview
9.4.3. Product Benchmarking
9.4.4. Key Developments
9.5. Biocon
9.5.1. Company Overview
9.5.2. Financial Overview
9.5.3. Product Benchmarking
9.5.4. Key Developments
9.6. Bionomics
9.6.1. Company Overview
9.6.2. Financial Overview
9.6.3. Product Benchmarking
9.6.4. Key Developments
9.7. CASI Pharmaceuticals
9.7.1. Company Overview
9.7.2. Financial Overview
9.7.3. Product Benchmarking
9.7.4. Key Developments
9.8. Celgene Corporation
9.8.1. Company Overview
9.8.2. Financial Overview
9.8.3. Product Benchmarking
9.8.4. Key Developments
9.9. Enzon Pharmaceuticals
9.9.1. Company Overview
9.9.2. Financial Overview
9.9.3. Product Benchmarking
9.9.4. Key Developments
9.10. Five Prime Therapeutics
9.10.1. Company Overview
9.10.2. Financial Overview
9.10.3. Product Benchmarking
9.10.4. Key Developments

10. Key Insights

Content are not available

Choose License Type